U.S. Markets closed

Alector, Inc. (ALEC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.00+1.50 (+9.68%)
At close: 4:00PM EDT

19.99 +2.99 (17.59%)
After hours: 7:54PM EDT

Alector, Inc.

131 Oyster Point Boulevard
Suite 600
South San Francisco, CA 94080
United States
415 231 5660
http://www.alector.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees171

Key Executives

NameTitlePayExercisedYear Born
Dr. Tillman U. GerngrossCo-Founder & Chairman49.44kN/A1964
Dr. Arnon RosenthalCo-Founder, CEO & Director869.81kN/A1956
Dr. Robert Paul M.D., Ph.D.Chief Medical Officer581.55kN/A1968
Dr. Robert S. KingChief Devel. Officer531.57kN/A1963
Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A.Pres, COO & Interim Chief Bus. OfficerN/AN/A1972
Mr. Calvin YuVP of Fin.N/AN/A1976
Mr. Charles WolfusVP of Technology & Digital HealthN/AN/AN/A
Mr. Brian Sander J.D., Ph.D.Gen. CounselN/AN/AN/A
Erica JeffersonVP of Communications & Public AffairsN/AN/AN/A
Ms. Clare Hunt M.B.A.Head of PeopleN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.

Corporate Governance

Alector, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.